La aludida resolución, en su parte conducente, es al tenor siguiente:
CÓDIGO FEDERAL DE INSTITUCIONES Y PROCEDIMIENTOS ELECTORALES
The development of effective antimicrobial agents from human salivary antimicrobial peptides is the ultimate goal of this thesis. It is expected that the new antimicrobial products can be used in vivo as compounds of artificial saliva, mouth rinse or other oral health products for therapeutic purposes. As a first step to meet this goal, more research is needed to obtain fundamental information on the potential of MUC7
peptide as a therapeutic agent. This thesis is focused on the in vitro antimicrobial activity of salivary mucins MUC7 derived peptides and deals with question such as: a) what are the effects of molecular and host physiological factors on the antimicrobial activity of MUC7 peptides? b) how to make MUC7 peptides work efficiently under physiological conditions? c) can the MUC7 peptides be used in the control of dental biofilm? d) what is the toxicity of the MUC7 peptides to the hosts?
More precisely, the specific objectives of this study are to determine:
1. the minimum peptide chain length and its location within the MUC7 20-mer region that retains antifungal activity and to examine the effect of cysteine residues on the fungicidal activity of MUC7 derived peptides (Chapter 2);
2. the antifungal activity of MUC7 peptides under physiological like conditions (Chapter 3);
3. the microbial source of proteases that are released into saliva (Chapter 4); 4. the effects of saliva on the stability of MUC7 peptides and to test the enhancement of antifungal activity of MUC7 peptides through protease inhibitors (Chapter 5);
5. the synergic antifungal effect of MUC7 peptides in combination with other antifungal agents (Chapter 6);
6. the inhibiting effect of MUC7 peptides on the growth of oral bacteria and on mutans streptococci biofilms (Chapter 7);
7. the cytotoxicity of MUC7 peptides to normal human erythrocytes and oral keratinocytes (Chapter 5 and 6).
REFERENCES
1. Armstrong GL, Conn LA, Pinner RW: Trends in infectious disease mortality in the United States during the 20th century. Jama 1999, 281(1):61-66.
2. O'Dowd A: Infectious diseases are spreading more rapidly than ever before, WHO warns.
BMJ 2007, 335(7617):418.
3. Perlroth J, Choi B, Spellberg B: Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 2007, 45(4):321-346.
4. Pfaller MA, Diekema DJ: Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007, 20(1):133-163.
5. Sturtevant J: Translation elongation-3-like factors: are they rational antifungal targets?
Expert Opin Ther Targets 2002, 6(5):545-553.
6. Ostrosky-Zeichner L, Rex JH, Bennett J, Kullberg BJ: Deeply invasive candidiasis. Infect Dis
Clin North Am 2002, 16(4):821-835.
7. Ellepola AN, Samaranayake LP: Oral candidal infections and antimycotics. Crit Rev Oral
Biol Med 2000, 11(2):172-198.
8. Coogan MM, Fidel PL, Jr., Komesu MC, Maeda N, Samaranayake LP: (B1) Candida and mycotic infections. Adv Dent Res 2006, 19(1):130-138.
9. Hodgson TA, Rachanis CC: Oral fungal and bacterial infections in HIV-infected individuals: an overview in Africa. Oral Dis 2002, 8 Suppl 2:80-87.
10. Patel M, Shackleton JT, Coogan MM: Effect of antifungal treatment on the prevalence of yeasts in HIV-infected subjects. J Med Microbiol 2006, 55(Pt 9):1279-1284.
11. Sanglard D, Odds FC: Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002, 2(2):73-85.
12. Ostrosky-Zeichner L, Pappas PG: Invasive candidiasis in the intensive care unit. Crit Care
Med 2006, 34(3):857-863.
13. Stoyan T, Carbon J: Inner kinetochore of the pathogenic yeast Candida glabrata. Eukaryot
Cell 2004, 3(5):1154-1163.
14. Mitchell TG, Perfect JR: Cryptococcosis in the era of AIDS--100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995, 8(4):515-548.
15. Collazos J: Opportunistic infections of the CNS in patients with AIDS: diagnosis and management. CNS Drugs 2003, 17(12):869-887.
16. Lakshmi V, Sudha T, Teja VD, Umabala P: Prevalence of central nervous system cryptococcosis in human immunodeficiency virus reactive hospitalized patients. Indian
J Med Microbiol 2007, 25(2):146-149.
17. Groll AH, Kolve H: Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Clin Microbiol Infect Dis 2004, 23(4):256-270. 18. Ghannoum MA, Rice LB: Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999, 12(4):501-517.
19. Georgopapadakou NH, Walsh TJ: Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrobial agents and chemotherapy 1996, 40(2):279-291. 20. Meyer RD: Current role of therapy with amphotericin B. Clin Infect Dis 1992, 14 Suppl
1:S154-160.
21. Joly V, Bolard J, Yeni P: In vitro models for studying toxicity of antifungal agents.
Antimicrobial agents and chemotherapy 1992, 36(9):1799-1804.
22. Boucher HW, Groll AH, Chiou CC, Walsh TJ: Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. Drugs 2004, 64(18):1997-2020.
23. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT et al: Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007, 356(4):348-359.
24. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N et al: Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007, 356(4):335-347. 25. Barchiesi F, Maracci M, Radi B, Arzeni D, Baldassarri I, Giacometti A, Scalise G: Point
prevalence, microbiology and fluconazole susceptibility patterns of yeast isolates colonizing the oral cavities of HIV-infected patients in the era of highly active antiretroviral therapy. J Antimicrob Chemother 2002, 50(6):999-1002.
26. Sobel JD, Ohmit SE, Schuman P, Klein RS, Mayer K, Duerr A, Vazquez JA, Rampalo A: The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis 2001, 183(2):286-293.
27. Sterling TR, Merz WG: Resistance to amphotericin B: emerging clinical and microbiological patterns. Drug Resist Updat 1998, 1(3):161-165.
28. Rex JH, Rinaldi MG, Pfaller MA: Resistance of Candida species to fluconazole.
Antimicrobial agents and chemotherapy 1995, 39(1):1-8.
29. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Doern GV, Brandt ME, Hajjeh RA: Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn Microbiol Infect Dis 1999, 33(4):217-222. 30. Archive for the ‘Infectious Diseases’ Category: Surveillance and control of infectious
diseases [http://www.lases.org/category/infectious-diseases]
31. Merck: Infections-Antibiotics In: The Merck Manual of Medical Information Edited by Porter RS, 2nd edn. Whitehouse Station, N.J. : Merck Research Laboratories 2003.
32. Guggenheim B, Giertsen E, Schupbach P, Shapiro S: Validation of an in vitro biofilm model of supragingival plaque. J Dent Res 2001, 80(1):363-370.
33. Shapiro S, Giertsen E, Guggenheim B: An in vitro oral biofilm model for comparing the efficacy of antimicrobial mouthrinses. Caries Res 2002, 36(2):93-100.
34. Multi-drug resistant bacteria create continual need for new antibiotics [http://findarticles.com/p/articles/mi_m0FSS/is_3_10/ai_n18612069/print]
35. Cudic M, Condie BA, Weiner DJ, Lysenko ES, Xiang ZQ, Insug O, Bulet P, Otvos L: Development of novel antibacterial peptides that kill resistant isolates. Peptides 2002, 23(12):2071-2083.
36. De Lucca AJ: Antifungal peptides: potential candidates for the treatment of fungal infections. Expert Opin Investig Drugs 2000, 9(2):273-299.
37. Hancock RE, Sahl HG: Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol 2006, 24(12):1551-1557.
38. Tossi A, Sandri L: Molecular diversity in gene-encoded, cationic antimicrobial polypeptides. Curr Pharm Des 2002, 8(9):743-761.
39. Andreu D, Rivas L: Animal antimicrobial peptides: an overview. Biopolymers 1998, 47(6):415-433.
40. van 't Hof W, Veerman EC, Helmerhorst EJ, Amerongen AV: Antimicrobial peptides: properties and applicability. Biol Chem 2001, 382(4):597-619.
41. Hancock RE, Brown KL, Mookherjee N: Host defence peptides from
invertebrates--emerging antimicrobial strategies. Immunobiology 2006, 211(4):315-322. 42. Glukhov E, Stark M, Burrows LL, Deber CM: Basis for selectivity of cationic antimicrobial
peptides for bacterial versus mammalian membranes. J Biol Chem 2005, 280(40):33960-33967.
43. Hancock RE, Lehrer R: Cationic peptides: a new source of antibiotics. Trends Biotechnol 1998, 16(2):82-88.
44. Brogden KA: Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?
Nat Rev Microbiol 2005, 3(3):238-250.
45. Jenssen H, Hamill P, Hancock RE: Peptide antimicrobial agents. Clin Microbiol Rev 2006, 19(3):491-511.
46. Yeaman MR, Yount NY: Mechanisms of antimicrobial peptide action and resistance.
Pharmacol Rev 2003, 55(1):27-55.
47. Radek K, Gallo R: Antimicrobial peptides: natural effectors of the innate immune system.
Semin Immunopathol 2007, 29(1):27-43.
48. Van Nieuw Amerongen A, Bolscher JG, Veerman EC: Salivary proteins: protective and diagnostic value in cariology? Caries Res 2004, 38(3):247-253.
49. Mandel ID: The functions of saliva. J Dent Res 1987, 66 Spec No:623-627.
50. Oppenheim FG, Xu T, McMillian FM, Levitz SM, Diamond RD, Offner GD, Troxler RF: Histatins, a novel family of histidine-rich proteins in human parotid secretion. Isolation, characterization, primary structure, and fungistatic effects on Candida albicans. J Biol
Chem 1988, 263(16):7472-7477.
51. Gusman H, Leone C, Helmerhorst EJ, Nunn M, Flora B, Troxler RF, Oppenheim FG: Human salivary gland-specific daily variations in histatin concentrations determined by a novel quantitation technique. Arch Oral Biol 2004, 49(1):11-22.
52. Helmerhorst EJ, Alagl AS, Siqueira WL, Oppenheim FG: Oral fluid proteolytic effects on histatin 5 structure and function. Arch Oral Biol 2006, 51(12):1061-1070.
53. Sabatini LM, Azen EA: Histatins, a family of salivary histidine-rich proteins, are encoded by at least two loci (HIS1 and HIS2). Biochem Biophys Res Commun 1989, 160(2):495-502. 54. Castagnola M, Inzitari R, Rossetti DV, Olmi C, Cabras T, Piras V, Nicolussi P, Sanna MT,
Pellegrini M, Giardina B et al: A cascade of 24 histatins (histatin 3 fragments) in human saliva. Suggestions for a pre-secretory sequential cleavage pathway. J Biol Chem 2004, 279(40):41436-41443.
55. Pollock JJ, Denepitiya L, MacKay BJ, Iacono VJ: Fungistatic and fungicidal activity of human parotid salivary histidine-rich polypeptides on Candida albicans. Infect Immun 1984, 44(3):702-707.
56. Tsai H, Bobek LA: Human salivary histatins: promising anti-fungal therapeutic agents.
Crit Rev Oral Biol Med 1998, 9(4):480-497.
57. Tsai H, Bobek LA: Human salivary histatin-5 exerts potent fungicidal activity against Cryptococcus neoformans. Biochimica et biophysica acta 1997, 1336(3):367-369.
58. Tsai H, Bobek LA: Studies of the mechanism of human salivary histatin-5 candidacidal activity with histatin-5 variants and azole-sensitive and -resistant Candida species.
Antimicrobial agents and chemotherapy 1997, 41(10):2224-2228.
59. Helmerhorst EJ, Reijnders IM, van't Hof W, Simoons-Smit I, Veerman EC, Amerongen AV: Amphotericin B- and fluconazole-resistant Candida spp., Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides.
Antimicrobial agents and chemotherapy 1999, 43(3):702-704.
60. MacKay BJ, Denepitiya L, Iacono VJ, Krost SB, Pollock JJ: Growth-inhibitory and bactericidal effects of human parotid salivary histidine-rich polypeptides on Streptococcus mutans. Infect Immun 1984, 44(3):695-701.
61. Xu T, Telser E, Troxler RF, Oppenheim FG: Primary structure and anticandidal activity of the major histatin from parotid secretion of the subhuman primate, Macaca fascicularis.
J Dent Res 1990, 69(11):1717-1723.
62. Murakami Y, Nagata H, Amano A, Takagaki M, Shizukuishi S, Tsunemitsu A, Aimoto S: Inhibitory effects of human salivary histatins and lysozyme on coaggregation between Porphyromonas gingivalis and Streptococcus mitis. Infect Immun 1991, 59(9):3284-3286. 63. Nishikata M, Kanehira T, Oh H, Tani H, Tazaki M, Kuboki Y: Salivary histatin as an inhibitor
of a protease produced by the oral bacterium Bacteroides gingivalis. Biochem Biophys
Res Commun 1991, 174(2):625-630.
64. Gusman H, Lendenmann U, Grogan J, Troxler RF, Oppenheim FG: Is salivary histatin 5 a metallopeptide? Biochimica et biophysica acta 2001, 1545(1-2):86-95.
65. Murakami Y, Xu T, Helmerhorst EJ, Ori G, Troxler RF, Lally ET, Oppenheim FG: Inhibitory effect of synthetic histatin 5 on leukotoxin from Actinobacillus actinomycetemcomitans.
Oral Microbiol Immunol 2002, 17(3):143-149.
66. Rydengard V, Andersson Nordahl E, Schmidtchen A: Zinc potentiates the antibacterial effects of histidine-rich peptides against Enterococcus faecalis. FEBS J 2006, 273(11):2399-2406.
67. Giacometti A, Cirioni O, Kamysz W, D'Amato G, Silvestri C, Del Prete MS, Licci A, Riva A, Lukasiak J, Scalise G: In vitro activity of the histatin derivative P-113 against multidrug-resistant pathogens responsible for pneumonia in immunocompromised patients. Antimicrobial agents and chemotherapy 2005, 49(3):1249-1252.
68. Ruissen AL, Groenink J, Helmerhorst EJ, Walgreen-Weterings E, Van't Hof W, Veerman EC, Nieuw Amerongen AV: Effects of histatin 5 and derived peptides on Candida albicans.
Biochem J 2001, 356(Pt 2):361-368.
69. Sajjan US, Tran LT, Sole N, Rovaldi C, Akiyama A, Friden PM, Forstner JF, Rothstein DM: P-113D, an antimicrobial peptide active against Pseudomonas aeruginosa, retains activity in the presence of sputum from cystic fibrosis patients. Antimicrobial agents and
chemotherapy 2001, 45(12):3437-3444.
70. Den Hertog AL, Wong Fong Sang HW, Kraayenhof R, Bolscher JG, Van't Hof W, Veerman EC, Nieuw Amerongen AV: Interactions of histatin 5 and histatin 5-derived peptides with liposome membranes: surface effects, translocation and permeabilization. Biochem J 2004, 379(Pt 3):665-672.
71. Helmerhorst EJ, van't Hof W, Breeuwer P, Veerman EC, Abee T, Troxler RF, Amerongen AV, Oppenheim FG: Characterization of histatin 5 with respect to amphipathicity, hydrophobicity, and effects on cell and mitochondrial membrane integrity excludes a candidacidal mechanism of pore formation. J Biol Chem 2001, 276(8):5643-5649. 72. Veerman EC, Valentijn-Benz M, Nazmi K, Ruissen AL, Walgreen-Weterings E, van Marle J,
Doust AB, van't Hof W, Bolscher JG, Amerongen AV: Energy depletion protects Candida albicans against antimicrobial peptides by rigidifying its cell membrane. J Biol Chem 2007, 282(26):18831-18841.
73. Edgerton M, Koshlukova SE, Araujo MW, Patel RC, Dong J, Bruenn JA: Salivary histatin 5 and human neutrophil defensin 1 kill Candida albicans via shared pathways.
Antimicrobial agents and chemotherapy 2000, 44(12):3310-3316.
74. Edgerton M, Koshlukova SE, Lo TE, Chrzan BG, Straubinger RM, Raj PA: Candidacidal activity of salivary histatins. Identification of a histatin 5-binding protein on Candida albicans. J Biol Chem 1998, 273(32):20438-20447.
75. Li XS, Reddy MS, Baev D, Edgerton M: Candida albicans Ssa1/2p is the cell envelope binding protein for human salivary histatin 5. J Biol Chem 2003, 278(31):28553-28561. 76. Helmerhorst EJ, Breeuwer P, van't Hof W, Walgreen-Weterings E, Oomen LC, Veerman EC,
Amerongen AV, Abee T: The cellular target of histatin 5 on Candida albicans is the energized mitochondrion. J Biol Chem 1999, 274(11):7286-7291.
77. Baev D, Li XS, Dong J, Keng P, Edgerton M: Human salivary histatin 5 causes disordered volume regulation and cell cycle arrest in Candida albicans. Infect Immun 2002, 70(9):4777-4784.
78. Baev D, Rivetta A, Vylkova S, Sun JN, Zeng GF, Slayman CL, Edgerton M: The TRK1 potassium transporter is the critical effector for killing of Candida albicans by the cationic protein, Histatin 5. J Biol Chem 2004, 279(53):55060-55072.
79. Koshlukova SE, Araujo MW, Baev D, Edgerton M: Released ATP is an extracellular cytotoxic mediator in salivary histatin 5-induced killing of Candida albicans. Infect
Immun 2000, 68(12):6848-6856.
80. Koshlukova SE, Lloyd TL, Araujo MW, Edgerton M: Salivary histatin 5 induces non-lytic release of ATP from Candida albicans leading to cell death. J Biol Chem 1999, 274(27):18872-18879.
81. Paquette DW, Waters GS, Stefanidou VL, Lawrence HP, Friden PM, O'Connor SM, Sperati JD, Oppenheim FG, Hutchens LH, Williams RC: Inhibition of experimental gingivitis in beagle dogs with topical salivary histatins. J Clin Periodontol 1997, 24(4):216-222.
82. Welling MM, Brouwer CP, van 't Hof W, Veerman EC, Amerongen AV: Histatin-derived monomeric and dimeric synthetic peptides show strong bactericidal activity towards multidrug-resistant Staphylococcus aureus in vivo. Antimicrobial agents and
chemotherapy 2007, 51(9):3416-3419.
83. Intini G, Aguirre A, Bobek LA: Efficacy of human salivary mucin MUC7-derived peptide and histatin 5 in a murine model of candidiasis. Int J Antimicrob Agents 2003, 22(6):594-600. 84. Mickels N, McManus C, Massaro J, Friden P, Braman V, D'Agostino R, Oppenheim F,
Warbington M, Dibart S, Van Dyke T: Clinical and microbial evaluation of a histatin-containing mouthrinse in humans with experimental gingivitis. J Clin Periodontol 2001, 28(5):404-410.
85. Van Dyke T, Paquette D, Grossi S, Braman V, Massaro J, D'Agostino R, Dibart S, Friden P: Clinical and microbial evaluation of a histatin-containing mouthrinse in humans with experimental gingivitis: a phase-2 multi-center study. J Clin Periodontol 2002, 29(2):168-176.
86. Rothstein DM, Spacciapoli P, Tran LT, Xu T, Roberts FD, Dalla Serra M, Buxton DK, Oppenheim FG, Friden P: Anticandida activity is retained in P-113, a 12-amino-acid fragment of histatin 5. Antimicrobial agents and chemotherapy 2001, 45(5):1367-1373. 87. Sasaki M, Ikeda H, Nakanuma Y: Expression profiles of MUC mucins and trefoil factor
family (TFF) peptides in the intrahepatic biliary system: physiological distribution and pathological significance. Prog Histochem Cytochem 2007, 42(2):61-110.
88. Gendler SJ, Spicer AP: Epithelial mucin genes. Annu Rev Physiol 1995, 57:607-634. 89. Kim YS, Gum JR, Jr., Crawley SC, Deng G, Ho JJ: Mucin gene and antigen expression in
biliopancreatic carcinogenesis. Ann Oncol 1999, 10 Suppl 4:51-55.
90. Rose MC: Epithelial mucous glycoproteins and cystic fibrosis. Horm Metab Res 1988, 20(10):601-608.
91. Choudhury A, Moniaux N, Winpenny JP, Hollingsworth MA, Aubert JP, Batra SK: Human MUC4 mucin cDNA and its variants in pancreatic carcinoma. J Biochem (Tokyo) 2000, 128(2):233-243.
92. Zalewska A, Zwierz K, Zolkowski K, Gindzienski A: Structure and biosynthesis of human salivary mucins. Acta Biochim Pol 2000, 47(4):1067-1079.
93. Levine MJ: Salivary macromolecules. A structure/function synopsis. Ann N Y Acad Sci 1993, 694:11-16.
94. Schenkels LCPM, Gururaja TL, Levine MJ: Salivary mucins: their role in oral mucosal barrier function and drug delivery. In: Oral Mucosal Drug Delivery. New York: Marcel Dekker, Inc.; 1996: 191-220.
95. Bobek LA, Tsai H, Biesbrock AR, Levine MJ: Molecular cloning, sequence, and specificity of expression of the gene encoding the low molecular weight human salivary mucin (MUC7). J Biol Chem 1993, 268(27):20563-20569.
96. Bobek LA, Liu J, Sait SN, Shows TB, Bobek YA, Levine MJ: Structure and chromosomal localization of the human salivary mucin gene, MUC7. Genomics 1996, 31(3):277-282. 97. Biesbrock AR, Bobek LA, Levine MJ: MUC7 gene expression and genetic polymorphism.
Glycoconj J 1997, 14(4):415-422.
98. Bobek LA, Li H, Rojstaczer N, Jones C, Gross KW, Levine MJ: Tissue-specific expression of human salivary mucin gene, MUC7, in transgenic mice. Transgenic Res 1998, 7(3):195-204.
99. Khan SH, Aguirre A, Bobek LA: In-situ hybridization localized MUC7 mucin gene expression to the mucous acinar cells of human and MUC7-transgenic mouse salivary glands. Glycoconj J 1998, 15(12):1125-1132.
100. Li S, Intini G, Bobek LA: Modulation of MUC7 mucin expression by exogenous factors in airway cells in vitro and in vivo. Am J Respir Cell Mol Biol 2006, 35(1):95-102.
101. Li S, Bobek LA: Functional analysis of human MUC7 mucin gene 5'-flanking region in lung epithelial cells. Am J Respir Cell Mol Biol 2006, 35(5):593-601.
102. Mehrotra R, Thornton DJ, Sheehan JK: Isolation and physical characterization of the MUC7 (MG2) mucin from saliva: evidence for self-association. Biochem J 1998, 334 ( Pt 2):415-422.
103. Tabak LA: In defense of the oral cavity: structure, biosynthesis, and function of salivary mucins. Annu Rev Physiol 1995, 57:547-564.
104. Tabak LA: Protein structure and function relationships: mucins. In: Oral Biology at the
Turn of the Century. B. Guggenheim and S. Shapiro, Ed. edn. Basel: S. Karger; 1998: 189-197.
105. Gururaja TL, Ramasubbu N, Venugopalan P, Reddy MS, Ramalingam K, Levine MJ: Structural features of the human salivary mucin, MUC7. Glycoconj J 1998, 15(5):457-467. 106. Satyanarayana J, Situ H, Narasimhamurthy S, Bhayani N, Bobek LA, Levine MJ: Divergent
solid-phase synthesis and candidacidal activity of MUC7 D1, a 51-residue histidine-rich N-terminal domain of human salivary mucin MUC7. J Pept Res 2000, 56(5):275-282. 107. Bobek LA, Situ H: MUC7 20-Mer: investigation of antimicrobial activity, secondary
structure, and possible mechanism of antifungal action. Antimicrobial agents and
chemotherapy 2003, 47(2):643-652.
108. Bobek LA: Schematic diagram of the structural features of MUC7 and derivation of MUC7 peptides. (Personal communication, December 2, 2003).
109. Gururaja TL, Levine JH, Tran DT, Naganagowda GA, Ramalingam K, Ramasubbu N, Levine MJ: Candidacidal activity prompted by N-terminus histatin-like domain of human salivary mucin (MUC7)1. Biochimica et biophysica acta 1999, 1431(1):107-119.
110. Situ H, Bobek LA: In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1. Antimicrobial
agents and chemotherapy 2000, 44(6):1485-1493.
111. Muralidharan R, Bobek LA: Antifungal activity of human salivary mucin-derived peptide, MUC7 12-mer, in a murine model of oral candidiasis. J Pept Res 2005, 66 Suppl 1:82-89. 112. Lee DG, Kim HN, Park Y, Kim HK, Choi BH, Choi CH, Hahm KS: Design of novel analogue
peptides with potent antibiotic activity based on the antimicrobial peptide, HP (2-20), derived from N-terminus of Helicobacter pylori ribosomal protein L1. Biochimica et
biophysica acta 2002, 1598(1-2):185-194.
113. Barchiesi F, Giacometti A, Cirioni O, Arzeni D, Silvestri C, Kamysz W, Abbruzzetti A, Riva A, Kamysz E, Scalise G: In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH(2) alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans. Peptides 2007, 28(8):1509-1513.
114. Nibbering PH, Danesi R, van 't Wout JW, van Dissel JT, Senesi S, Lupetti A: Antimicrobial peptides: therapeutic potential for the treatment of C andida infections. Expert Opin
Investig Drugs 2002, 11(2):309-318.
115. Wakabayashi H, Abe S, Okutomi T, Tansho S, Kawase K, Yamaguchi H: Cooperative anti-Candida effects of lactoferrin or its peptides in combination with azole antifungal agents. Microbiol Immunol 1996, 40(11):821-825.
Hongsa Situ, Guoxian Wei, Christina J. Smith, Shirin Mashhoon and Libuse A. Bobek
Biochemistry Journal 2003; 375: 175-182